AstraZeneca spins out biotech to focus on autoimmune candidatesAstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. Share XAstraZeneca spins out biotech to focus on autoimmune candidateshttps://pharmaphorum.com/news/astrazeneca-spins-biotech-focus-autoimmune-candidates/